These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

207 related articles for article (PubMed ID: 33817651)

  • 1. Improving Tumor Hypoxia Location in
    Gertsenshteyn I; Epel B; Barth E; Leoni L; Markiewicz E; Tsai HM; Fan X; Giurcanu M; Bodero D; Zamora M; Sundramoorthy S; Kim H; Freifelder R; Bhuiyan M; Kucharski A; Karczmar G; Kao CM; Halpern H; Chen CT
    Radiol Imaging Cancer; 2021 Mar; 3(2):e200104. PubMed ID: 33817651
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The optimal
    Gertsenshteyn I; Epel B; Ahluwalia A; Kim H; Fan X; Barth E; Zamora M; Markiewicz E; Tsai HM; Sundramoorthy S; Leoni L; Lukens J; Bhuiyan M; Freifelder R; Kucharski A; Giurcanu M; Roman BB; Karczmar G; Kao CM; Halpern H; Chen CT
    Eur J Nucl Med Mol Imaging; 2022 Oct; 49(12):4014-4024. PubMed ID: 35792927
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Effect of Neoadjuvant Androgen Deprivation Therapy on Tumor Hypoxia in High-Grade Prostate Cancer: An
    Mainta IC; Zilli T; Tille JC; De Perrot T; Vallée JP; Buchegger F; Garibotto V; Miralbell R
    Int J Radiat Oncol Biol Phys; 2018 Nov; 102(4):1210-1218. PubMed ID: 29678527
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluation of Tumor-associated Stroma and Its Relationship with Tumor Hypoxia Using Dynamic Contrast-enhanced CT and (18)F Misonidazole PET in Murine Tumor Models.
    Koyasu S; Tsuji Y; Harada H; Nakamoto Y; Nobashi T; Kimura H; Sano K; Koizumi K; Hamaji M; Togashi K
    Radiology; 2016 Mar; 278(3):734-41. PubMed ID: 26393963
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tumoral hypoxia in osteosarcoma in rats: preliminary study of blood oxygenation level-dependent functional MRI and 18F-misonidazole PET/CT with diffusion-weighted MRI correlation.
    Dallaudiere B; Hummel V; Hess A; Lincot J; Preux PM; Maubon A; Monteil J
    AJR Am J Roentgenol; 2013 Feb; 200(2):W187-92. PubMed ID: 23345383
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of DCE-MRI kinetic parameters and FMISO-PET uptake parameters in head and neck cancer patients.
    Simoncic U; Leibfarth S; Welz S; Schwenzer N; Schmidt H; Reischl G; Pfannenberg C; Fougère C; Nikolaou K; Zips D; Thorwarth D
    Med Phys; 2017 Jun; 44(6):2358-2368. PubMed ID: 28317128
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Optimal timing of fluorine-18-fluoromisonidazole positron emission tomography/computed tomography for assessment of tumor hypoxia in patients with head and neck squamous cell carcinoma.
    Chatterjee A; Gupta T; Rangarajan V; Purandare N; Kunder S; Murthy V; Budrukkar A; Ghosh-Laskar S; Agarwal J
    Nucl Med Commun; 2018 Sep; 39(9):859-864. PubMed ID: 29939883
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Monitoring Combretastatin A4-induced tumor hypoxia and hemodynamic changes using endogenous MR contrast and DCE-MRI.
    Colliez F; Fruytier AC; Magat J; Neveu MA; Cani PD; Gallez B; Jordan BF
    Magn Reson Med; 2016 Feb; 75(2):866-72. PubMed ID: 25765253
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation of quantitative imaging parameters in head and neck squamous cell carcinoma.
    Gupta T; Chatterjee A; Rangarajan V; Purandare N; Arya S; Murthy V; Budrukkar A; Ghosh-Laskar S; Agarwal JP
    Q J Nucl Med Mol Imaging; 2022 Jun; 66(2):162-170. PubMed ID: 31496204
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A prospective clinical trial of tumor hypoxia imaging with 18F-fluoromisonidazole positron emission tomography and computed tomography (F-MISO PET/CT) before and during radiation therapy.
    Tachibana I; Nishimura Y; Shibata T; Kanamori S; Nakamatsu K; Koike R; Nishikawa T; Ishikawa K; Tamura M; Hosono M
    J Radiat Res; 2013 Nov; 54(6):1078-84. PubMed ID: 23589026
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Simultaneous positron emission tomography (PET) assessment of metabolism with ¹⁸F-fluoro-2-deoxy-d-glucose (FDG), proliferation with ¹⁸F-fluoro-thymidine (FLT), and hypoxia with ¹⁸fluoro-misonidazole (F-miso) before and during radiotherapy in patients with non-small-cell lung cancer (NSCLC): a pilot study.
    Vera P; Bohn P; Edet-Sanson A; Salles A; Hapdey S; Gardin I; Ménard JF; Modzelewski R; Thiberville L; Dubray B
    Radiother Oncol; 2011 Jan; 98(1):109-16. PubMed ID: 21056487
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tumor hypoxia imaging in orthotopic liver tumors and peritoneal metastasis: a comparative study featuring dynamic 18F-MISO and 124I-IAZG PET in the same study cohort.
    Riedl CC; Brader P; Zanzonico P; Reid V; Woo Y; Wen B; Ling CC; Hricak H; Fong Y; Humm JL
    Eur J Nucl Med Mol Imaging; 2008 Jan; 35(1):39-46. PubMed ID: 17786438
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Noninvasive multimodality imaging of the tumor microenvironment: registered dynamic magnetic resonance imaging and positron emission tomography studies of a preclinical tumor model of tumor hypoxia.
    Cho H; Ackerstaff E; Carlin S; Lupu ME; Wang Y; Rizwan A; O'Donoghue J; Ling CC; Humm JL; Zanzonico PB; Koutcher JA
    Neoplasia; 2009 Mar; 11(3):247-59, 2p following 259. PubMed ID: 19242606
    [TBL] [Abstract][Full Text] [Related]  

  • 14. EPR oxygen images predict tumor control by a 50% tumor control radiation dose.
    Elas M; Magwood JM; Butler B; Li C; Wardak R; DeVries R; Barth ED; Epel B; Rubinstein S; Pelizzari CA; Weichselbaum RR; Halpern HJ
    Cancer Res; 2013 Sep; 73(17):5328-35. PubMed ID: 23861469
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Concurrent Respiratory Motion Correction of Abdominal PET and Dynamic Contrast-Enhanced-MRI Using a Compressed Sensing Approach.
    Fuin N; Catalano OA; Scipioni M; Canjels LPW; Izquierdo-Garcia D; Pedemonte S; Catana C
    J Nucl Med; 2018 Sep; 59(9):1474-1479. PubMed ID: 29371404
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Machine learning identifies multi-parametric functional PET/MR imaging cluster to predict radiation resistance in preclinical head and neck cancer models.
    Boeke S; Winter RM; Leibfarth S; Krueger MA; Bowden G; Cotton J; Pichler BJ; Zips D; Thorwarth D
    Eur J Nucl Med Mol Imaging; 2023 Aug; 50(10):3084-3096. PubMed ID: 37148296
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hypoxia and perfusion in breast cancer: simultaneous assessment using PET/MR imaging.
    Carmona-Bozo JC; Manavaki R; Woitek R; Torheim T; Baxter GC; Caracò C; Provenzano E; Graves MJ; Fryer TD; Patterson AJ; Gilbert FJ
    Eur Radiol; 2021 Jan; 31(1):333-344. PubMed ID: 32725330
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Methods for noninvasive imaging of tissue hypoxia.
    Vikram DS; Zweier JL; Kuppusamy P
    Antioxid Redox Signal; 2007 Oct; 9(10):1745-56. PubMed ID: 17663644
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Neoadjuvant chemotherapy in breast cancer: prediction of pathologic response with PET/CT and dynamic contrast-enhanced MR imaging--prospective assessment.
    Tateishi U; Miyake M; Nagaoka T; Terauchi T; Kubota K; Kinoshita T; Daisaki H; Macapinlac HA
    Radiology; 2012 Apr; 263(1):53-63. PubMed ID: 22438441
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Iodine-124-labeled iodo-azomycin-galactoside imaging of tumor hypoxia in mice with serial microPET scanning.
    Zanzonico P; O'Donoghue J; Chapman JD; Schneider R; Cai S; Larson S; Wen B; Chen Y; Finn R; Ruan S; Gerweck L; Humm J; Ling C
    Eur J Nucl Med Mol Imaging; 2004 Jan; 31(1):117-28. PubMed ID: 14523586
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.